文献速递眼底病与葡萄膜炎

CATT 试验事后分析:nAMD 治疗2年后停药3年仍保持良好视力的眼特征

Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该研究为 CATT 随机临床试验的事后病例对照分析,比较 40 只停药后 3 年仍保持良好视力(CTGVA 组)的眼与其余 585 只眼。CTGVA 组基线研究眼与对眼视力更好、年龄更轻,按需治疗组第 1、2 年注射次数更少,5 年视力更佳;基线未能识别可安全停药的特征。

要点

  • nAMD 治疗2年后停药3年仍保持良好视力者占 6.4%(95%CI 4.7%-8.7%)。
  • CTGVA 组基线研究眼视力字母分更高(68.8 vs 61.8,P=.001)。
  • 基线无法识别可停药且保持良好视力的独特特征,提示并非所有患眼都需终身治疗。

核心结论

  • 小部分 nAMD 眼在初始治疗2年后停药至少3年仍可保持良好视力。
  • 基线时无法识别哪些眼可停药并维持良好视力。
  • 数据提示并非所有 nAMD 眼都需要终身治疗。

研究设计与样本

  • 初始随机分配至雷珠单抗每月、贝伐珠单抗每月、雷珠单抗按需或贝伐珠单抗按需4组,第1年每月组再随机继续每月或改为同药按需。
  • 第2年退出方案由眼科医师酌情治疗,第5年召回检查,比较 40 只 CTGVA 眼与其余 585 只眼。

主要发现

  • 625 只基线 nAMD 眼且有第5年视力测量中,40 只(6.4%;95%CI 4.7%-8.7%)纳入分析。
  • CTGVA 组平均(SD)年龄 74.7(7.3)岁,低于其他组 77.7(7.3)岁(P=.01),其中女性 26 人(65.0%)。
  • 基线除研究眼视力字母分(68.8 vs 61.8;P=.001)、对眼(78.4 vs 68.0;P=.01)及阻断荧光(27.5% vs 13.8%;P=.02)外,两组基线特征相似。
  • CTGVA 组中按需治疗眼第1年平均(SD)注射 5.8(4.0)次 vs 8.1(3.5)次,第2年 7.7(5.7)次 vs 13.8(6.8)次,均少于其他按需组。
  • 第5年平均(SD)视力字母分 CTGVA 组 79.0(5.5;Snellen 20/25),其他组 57.5(24.2;Snellen 20/80)。

关键数值与推荐

  • CTGVA 定义为初始2年治疗结束后 3 年未接受治疗且保持良好视力。
  • CTRVA 组占 625 只眼的 6.4%(95%CI 4.7%-8.7%)。
  • 5 年视力:CTGVA 组 Snellen 20/25,其他组 Snellen 20/80。

临床怎么用

  • 对 nAMD 长期治疗者,部分眼在初始2年后可尝试停药并密切随访。
  • 基线视力较好、年龄较轻及存在阻断荧光者可能更可能属于可停药且视力良好人群。
  • 按需治疗中注射次数较少者或提示疾病活动度低,可考虑个体化减少治疗。

局限性

  • 为 CATT 事后分析,CTGVA 组仅 40 只眼,样本量小。
  • 基线未能识别可安全停药的独特特征,结论不能用于预测个体停药。
  • 停药后随访与治疗由医师酌情决定,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Identifying the characteristics of eyes with neovascular age-related macular degeneration (nAMD) that maintain good vision without anti-vascular endothelial growth factor treatment for at least 3 years after management, as occurred in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), may have prognostic importance and help in understanding the disease and its treatment. OBJECTIVES: To ascertain the characteristics of eyes in the CATT that retained good vision despite receiving no therapy for 3 years after release from the 2-year CATT treatment protocol. DESIGN, SETTING AND PARTICIPANTS: This case-control study analyzed the baseline and follow-up characteristics of eyes with nAMD that were enrolled in the CATT from 43 US clinical centers between February 20, 2008, and December 9, 2009. After initial randomization to 1 of 4 treatment groups (ranibizumab monthly, bevacizumab monthly, ranibizumab as needed, or bevacizumab as needed), at year 1, participants in the monthly groups were rerandomized to continue monthly treatment or to switch to as-needed treatment using the same drug as originally assigned. At year 2, participants were released from the protocol to treatment at the discretion of their ophthalmologist. At year 5, participants were recalled for examination. This present analysis, conducted from December 1, 2018, to September 30, 2019, compared the eyes of 40 participants (referred to as the cessation of treatment with good visual acuity, or CTGVA, group) with the eyes of the remainder of the CATT Follow-up Study (referred to as the other group). MAIN OUTCOMES AND MEASURES: Visual acuity, morphologic characteristics, and number of treatments over 5 years. RESULTS: Among 625 eyes with nAMD at baseline and a visual acuity measurement at year 5, 40 (6.4%; 95% CI, 4.7%-8.7%) were included in the analysis. These 40 participants, compared with the other group (n = 585), had a lower mean (SD) age of 74.7 (7.3) years (vs 77.7 [7.3] years; P = .01) and included 26 women (65.0%). Baseline characteristics were similar between eyes in the CTGVA and other groups, except for better visual acuity letter score in the study eye (68.8 vs 61.8; P = .001) and the fellow eye (78.4 vs 68.0; P = .01) as well as the presence of blocked fluorescence seen more often in participants in the CTGVA vs the other group (27.5% vs 13.8%; P = .02). Eyes in the CTGVA group with as-needed treatment received fewer mean (SD) injections in year 1 (5.8 [4.0] vs 8.1 [3.5]) and year 2 (7.7 [5.7] vs 13.8 [6.8]) than eyes in the other as-needed group. Mean (SD) visual acuity letter score at 5 years was 79.0 (5.5; Snellen 20/25) in the CTGVA group and 57.5 (24.2; Snellen 20/80) in the other group. CONCLUSIONS AND RELEVANCE: These findings suggest that a small proportion of eyes with nAMD can retain good visual acuity with no treatment for at least 3 years after the initial 2 years of treatment. Unique characteristics of eyes that could discontinue treatment while maintaining good visual acuity could not be identified at baseline, but data suggest that not all eyes with this disease may need treatment forever. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00593450.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Scoles D, Ying GS, Pan W, et al. Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 31999297. doi:10.1001/jamaophthalmol.2019.5831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。